Literature DB >> 18675885

Immunosuppressive networks in the tumour environment and their effect in dendritic cells.

Karim Bennaceur1, Jessica Alice Chapman, Jean-Louis Touraine, Jacques Portoukalian.   

Abstract

The failure of the immune system to provide protection against tumour cells is an important immunological problem. It is now evident that inadequate function of the host immune system is one of the main mechanisms by which tumours escape from immune control, as well as an important factor that limits the success of cancer immunotherapy. In recent years, it has become increasingly clear that defects in dendritic cells have a crucial role in non-responsiveness to tumours. This article focuses on the functional consequences and recently described mechanisms of the dendritic-cell defects in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675885     DOI: 10.1016/j.bbcan.2008.07.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Quantification of blood dendritic cells in colorectal cancer patients during the course of disease.

Authors:  Giulia Orsini; Annalisa Legitimo; Alessandra Failli; Paola Ferrari; Andrea Nicolini; Roberto Spisni; Paolo Miccoli; Rita Consolini
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

2.  Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.

Authors:  Y Liu; X Yun; M Gao; Y Yu; X Li
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

Review 3.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

Review 4.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

5.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Authors:  Neil Senzer; Minal Barve; Joseph Kuhn; Anton Melnyk; Peter Beitsch; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Jonathan Oh; Susan W Mill; Cynthia Bedell; Candice Higgs; Padmasini Kumar; Yang Yu; Fabienne Norvell; Connor Phalon; Nicolas Taquet; Donald D Rao; Zhaohui Wang; Chris M Jay; Beena O Pappen; Gladice Wallraven; F Charles Brunicardi; David M Shanahan; Phillip B Maples; John Nemunaitis
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

6.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

7.  IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.

Authors:  Heba A Alshaker; Khalid Z Matalka
Journal:  Cancer Cell Int       Date:  2011-09-23       Impact factor: 5.722

8.  Dendritic cell activation by glucan isolated from umbilicaria esculenta.

Authors:  Hyung Sook Kim; Jee Youn Kim; Hong Kyung Lee; Moo Sung Kim; Sang Rin Lee; Jong Soon Kang; Hwan Mook Kim; Kyung-Ae Lee; Jin Tae Hong; Youngsoo Kim; Sang-Bae Han
Journal:  Immune Netw       Date:  2010-12-31       Impact factor: 6.303

9.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

10.  Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.

Authors:  Parvin Forghani; Mohammad R Khorramizadeh; Edmund K Waller
Journal:  Cancer Med       Date:  2014-01-20       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.